Clinical trials
Autoimmune Hemolytic Anemia (AIHA) clinical trials
Below are recruiting autoimmune hemolytic anemia (aiha) clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05057468RecruitingPhase 3
Second-line treatment for warm autoimmune anemia
This Phase 3 study tests a second-line treatment for adults with warm autoimmune hemolytic anemia whose disease is not controlled with steroids, who cannot tolerate steroids, or who decline standard treatment. It aims to improve anemia and reduce ongoing red blood cell destruction caused by the immune system.
Asyut, Asyut GovernorateAges 18 years+ - NCT07530380RecruitingEarly Phase 1
CAR T-cell therapy for treatment-resistant autoimmune hemolytic anemia
This trial tests a new type of cell therapy called UCAR T-cells, which are immune cells engineered to target and destroy the B cells causing your body to attack its own red blood cells. It's designed for patients whose autoimmune hemolytic anemia hasn't responded to at least 3 standard treatments.
HefeiAges 10 years+ - NCT07748533RecruitingPhase 1
CAR T-cell therapy for hard-to-treat autoimmune hemolytic anemia
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
TianjinAges 18–75 - NCT07083960RecruitingPhase 1
Study of OM336 for low blood cell counts caused by immune system
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
Canberra, Australian Capital TerritoryAges 18–75 - NCT04645199Recruiting
Long-term follow-up study for blood and bone marrow diseases
This study is collecting long-term follow-up information from people diagnosed with certain blood and bone marrow conditions. It may help doctors understand what happens over time and improve future care, but you’re mainly contributing data rather than receiving a new treatment.
Tianjin, Tianjin MunicipalityAges Any age - NCT05089227RecruitingPhase 2
Long-term apixaban to prevent clots in autoimmune hemolytic anemia
This Phase 2 trial tests whether taking long-term apixaban (a blood thinner) can prevent venous blood clots in people with autoimmune hemolytic anemia (AIHA). It may help reduce the risk of dangerous clotting events if you meet safety and risk criteria.
DijonAges 18 years+ - NCT05937828Recruiting
Caring for children with autoimmune blood disorders in France
This study follows children and teens who have certain autoimmune blood conditions to better understand their illness. It may help doctors learn how these conditions behave over time and improve care.
AmiensAges Up to 17 years - NCT06921980Recruiting
Cell therapy and brain function in AIHA
This trial looks at how cell therapy may affect your brain function and mood if you have autoimmune hemolytic anemia. It aims to help doctors understand the psychological changes that can happen during treatment.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07019038Recruiting
Autoimmune hemolytic anemia long-term study
This study looks at people with autoimmune hemolytic anemia (AIHA) over time. It aims to understand the disease better and find ways to improve care.
Tianjin, Tianjin MunicipalityAges Any age - NCT07175493RecruitingPhase 1/Phase 2
CM336 for relapsed or refractory autoimmune cytopenia
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
Zhengzhou, HenanAges 18 years+ - NCT07205315RecruitingEarly Phase 1
Testing GT801 cell therapy for blood cancer and AIHA
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
Zhengzhou, HenanAges 18–75 - NCT07441525RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat autoimmune blood diseases
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
Wuhan, HubeiAges 18–75 - NCT07453368RecruitingPhase 2
Orelabrutinib for relapsed or hard-to-treat AIHA
This trial tests a targeted pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that has come back or not responded to standard treatments. It may help control your immune system's attack on your red blood cells.
Beijing, Beijing MunicipalityAges 18–85 - NCT07629596RecruitingEarly Phase 1
mRNA CAR-T therapy for severe lupus or autoimmune anemia
This early-stage trial tests a new mRNA-based therapy called Arnovie101 that trains your immune cells to fight lupus (SLE) or autoimmune hemolytic anemia (AIHA) that haven't improved with standard treatments. The therapy may help reduce disease activity and symptoms.
Beijing, Beijing MunicipalityAges 18–60 - NCT06733610RecruitingPhase 1
CAR T-cell therapy for AIHA after 3 failed treatments
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05694312RecruitingPhase 2
Ibrutinib for anemia caused by immune destruction in CLL/SLL
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
FlorenceAges 18 years+ - NCT07361094RecruitingPhase 1
CAR-T therapy for autoimmune disease after prior treatment
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
BeijingAges 18–70 - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+
Hear when a new Autoimmune Hemolytic Anemia (AIHA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmune hemolytic anemia (aiha)?
- Yes. Clin2 currently lists 18 recruiting autoimmune hemolytic anemia (aiha) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmune hemolytic anemia (aiha) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmune hemolytic anemia (aiha) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.